FSA Wealth Management LLC Acquires New Position in Pfizer Inc. (NYSE:PFE)

FSA Wealth Management LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,898 shares of the biopharmaceutical company’s stock, valued at approximately $142,000.

Several other institutional investors also recently bought and sold shares of the business. Lavaca Capital LLC boosted its holdings in shares of Pfizer by 3.6% during the third quarter. Lavaca Capital LLC now owns 11,980 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 416 shares during the last quarter. B&L Asset Management LLC acquired a new stake in Pfizer in the 3rd quarter worth about $397,000. Erste Asset Management GmbH purchased a new stake in Pfizer in the 3rd quarter valued at about $16,776,000. Socorro Asset Management LP increased its stake in shares of Pfizer by 17.9% during the 3rd quarter. Socorro Asset Management LP now owns 266,951 shares of the biopharmaceutical company’s stock valued at $7,726,000 after acquiring an additional 40,545 shares during the last quarter. Finally, Semmax Financial Advisors Inc. lifted its holdings in shares of Pfizer by 3.2% during the 3rd quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company’s stock worth $2,695,000 after acquiring an additional 3,185 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Citigroup started coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Finally, Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Shares of PFE stock opened at $26.21 on Friday. The firm has a fifty day simple moving average of $27.83 and a 200-day simple moving average of $28.49. The company has a market capitalization of $148.53 billion, a PE ratio of 35.42, a price-to-earnings-growth ratio of 0.71 and a beta of 0.67. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the firm earned ($0.17) earnings per share. The company’s revenue was up 31.2% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.41%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.